Prescription Drug Pricing Trends and Policy Changes

Affordability remains unsettled: Medicare's 2027 negotiated prices include a reported Janumet reduction from $526 to $80, while Medicaid agreements reportedly involve 26 manufacturers covering 89% of branded-market sales. The reported $50 Wegovy/Zepbound Bridge pathway has important BMI, prior-authorization, coverage, duration, and Part D accounting limits. Medicare open enrollment and pharmacist-prescriber coordination are increasingly important for comparing formularies, networks, covered alternatives, and total costs.